Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791

Inflammation and metabolic disorders

Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199

Toll-like receptor signalling

Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312

Extracellular vesicles: Exosomes, microvesicles, and friends

Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099

Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes

Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837

TLR4 links innate immunity and fatty acid-induced insulin resistance

Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416

A central role for JNK in obesity and insulin resistance

Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359

Mechanisms of NAFLD development and therapeutic strategies

Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354

Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease

Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C. A., Chevet, É., & Bailly‐Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 971

Triggering and resolution of inflammation in NASH

Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943

Lipotoxicity and the gut-liver axis in NASH pathogenesis

Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847

Molecular pathways of nonalcoholic fatty liver disease development and progression

Bessone, F., Razori, M. V., & Roma, M. G. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 664

Recent insights into the pathogenesis of nonalcoholic fatty liver disease

Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573

Past, present and future perspectives in nonalcoholic fatty liver disease

Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522

Pathophysiology of obesity and its associated diseases

Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C. G., & Jiang, T. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.012 · Cited by 603

Determinants of Fibrosis Progression and Regression in NASH

Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479

Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH

Pierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 473

Non-alcoholic fatty liver disease

Neuschwander‐Tetri, B. A. (2017) · BMC Medicine · doi:10.1186/s12916-017-0806-8 · Cited by 470

How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?

Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. J. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 465

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387

Challenges and opportunities in NASH drug development

Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353

Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation–Mediated Cell Death in Mice

Qi, J., Kim, J.-W., Zhou, Z., Lim, C.-W., & Kim, B. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.09.011 · Cited by 338

High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms

Lian, C.-Y., Zhai, Z., Li, Z., & Wang, L. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109199 · Cited by 325

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation

Ibrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278

Apoptosis and non-alcoholic fatty liver diseases

Kanda, T., Matsuoka, S., Yamazaki, M., Shibata, T., Nirei, K., Takahashi, H., Kaneko, T., Fujisawa, M., Higuchi, T., Nakamura, H., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2661 · Cited by 269

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.024 · Cited by 260

Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease

Svegliati‐Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 255

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Lee, K., Wu, P.-S., & Lin, H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 269

The circadian clock and liver function in health and disease

Mukherji, A., Bailey, S. M., Staels, B., & Baumert, T. F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.020 · Cited by 246

Macrophage functional diversity in NAFLD — more than inflammation

Barreby, E., Chen, P., & Aouadi, M. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00675-6 · Cited by 251

Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies

Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239

Novel therapeutic targets for cholestatic and fatty liver disease

Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204

IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis

Dasgupta, D., Nakao, Y., Mauer, A. S., Thompson, J., Sehrawat, T. S., Liao, C., Krishnan, A., Lucien, F., Guo, Q., Liu, M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.031 · Cited by 188

Therapeutic Landscape for NAFLD in 2020

Neuschwander‐Tetri, B. A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.051 · Cited by 184

Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management

Cholankeril, G. T., Patel, R., Khurana, S., & Satapathy, S. K. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i11.533 · Cited by 185

Cell Culture Models of Fatty Acid Overload: Problems and Solutions

Alsabeeh, N., Chausse, B., Kakimoto, P. A., Kowaltowski, A. J., & Shirihai, O. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.11.006 · Cited by 167

Sphingolipids and glycerophospholipids – The “ying and yang” of lipotoxicity in metabolic diseases

Rodríguez‐Cuenca, S., Pellegrinelli, V., Campbell, M., Orešič, M., & Vidal‐Puig, A. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.01.002 · Cited by 153

NAFLD: Reporting Histologic Findings in Clinical Practice

Brunt, E. M., Kleiner, D. E., Carpenter, D. H., Rinella, M. E., Harrison, S. A., Loomba, R. S., Younossi, Z. M., Neuschwander‐Tetri, B. A., & Sanyal, A. J. (2020) · Hepatology · doi:10.1002/hep.31599 · Cited by 153

Manifestations and mechanisms of myocardial lipotoxicity in obesity

Sletten, A. C., Peterson, L. R., & Schaffer, J. E. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12728 · Cited by 148

The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease

Song, M. J., & Malhi, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107401 · Cited by 146

Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options

Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 167

Green Tea Polyphenol EGCG Alleviates Metabolic Abnormality and Fatty Liver by Decreasing Bile Acid and Lipid Absorption in Mice

Huang, J., Feng, S., Liu, A., Dai, Z., Wang, H., Reuhl, K. R., Lu, W., & Yang, C. S. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700696 · Cited by 144

Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source

Boland, M. L., Oró, D., Tølbøl, K. S., Thrane, S. T., Nielsen, J. C., Cohen, T. S., Tabor, D. E., Fernandes, F., Tovchigrechko, A., Veidal, S. S., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4904 · Cited by 129

Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity

INSERM, U., & Fromenty, B. (2017) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.2017s1.006 · Cited by 124

Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases

Martinez‐Uña, M., López‐Mancheño, Y., Diéguez, C., Fernandez-Rojo, M. A., & Novelle, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249368 · Cited by 120

Macronutrients and the Adipose-Liver Axis in Obesity and Fatty Liver

Duwaerts, C. C., & Maher, J. J. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.02.001 · Cited by 113

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease

Khambu, B., Yan, S., Huda, N., Liu, G., & Yin, X. (2018) · Liver Research · doi:10.1016/j.livres.2018.09.004 · Cited by 107

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma

Kutlu, Ö., Kaleli, H. N., & Ozer, E. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/8543763 · Cited by 105

Hepatocyte-Derived Lipotoxic Extracellular Vesicle Sphingosine 1-Phosphate Induces Macrophage Chemotaxis

Liao, C., Song, M. J., Gao, Y., Mauer, A. S., Revzin, A., & Malhi, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02980 · Cited by 99

Emerging role of aging in the progression of NAFLD to HCC

He, Y., Su, Y., Duan, C., Wang, S., He, W. G., Zhang, Y., An, X., & He, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101833 · Cited by 100

Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease

Yang, J., Hirai, Y., Iida, K., Ito, S., Trumm, M., Terada, S., Sakai, R., Tsuchiya, T., Tabata, O., & Kamei, K.-I. (2023) · Communications Biology · doi:10.1038/s42003-023-04710-8 · Cited by 98

Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH

Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94

Role of Leptin in Non-Alcoholic Fatty Liver Disease

Jiménez‐Cortegana, C., García-Galey, A., Tami, M., Bellido, P. D. P., Carmona, I., López, S., Álba, G., & Sánchez‐Margalet, V. (2021) · Biomedicines · doi:10.3390/biomedicines9070762 · Cited by 100

From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease

Zhou, M., Lv, J., Chen, X., Shi, Y., Chao, G., & Zhang, S. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101777 · Cited by 98

Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis

Sharma, S. K., Guillou, D. L., & Chen, J. Y. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00832-w · Cited by 100

Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)

Iturbe-Rey, S., Maccali, C., Arrese, M. A., Aspichueta, P., de Oliveira, C. P. M. S., Castro, R. E., Lapitz, A., Izquierdo‐Sánchez, L., Bujanda, L., Perugorria, M. J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119053 · Cited by 102

The metabolic basis of nonalcoholic steatohepatitis

Chakravarthy, M. V., & Neuschwander‐Tetri, B. A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.112 · Cited by 93

Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease

Mooli, R. G. R., & Ramakrishnan, S. K. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.946474 · Cited by 92

CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis

Shi, H., Wang, X., Li, F., Gerlach, B. D., Yurdagul, A., Moore, M. P., Zeldin, S., Zhang, H., Cai, B., Zheng, Z., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8309 · Cited by 85

Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research

Berardo, C., Pasqua, L. G. D., Cagna, M., Richelmi, P., Vairetti, M., & Ferrigno, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249646 · Cited by 89

To die or not to die: death signaling in nonalcoholic fatty liver disease

Akazawa, Y., & Nakao, K. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1451-5 · Cited by 81

Hepatocyte TNF Receptor–Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6–Linked Polyubiquitination of Apoptosis Signal‐Regulating Kinase 1

Wang, Y., Wen, H., Fu, J., Cai, L., Li, P., Zhao, C., Dong, Z., Ma, J., Wang, X., Tian, H., et al. (2019) · Hepatology · doi:10.1002/hep.30822 · Cited by 79

Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link

Chrysavgis, L., Giannakodimos, I., Diamantopoulou, P., & Cholongitas, Ε. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i3.310 · Cited by 84

Differential Lipotoxic Effects of Palmitate and Oleate in Activated Human Hepatic Stellate Cells and Epithelial Hepatoma Cells

Hetherington, A. M., Sawyez, C. G., Zilberman, E., Stoianov, A. M., Robson, D. L., & Borradaile, N. M. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447866 · Cited by 78

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches

Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 77

Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages

Drummer, C., Saaoud, F., Jhala, N. C., Cueto, R., Sun, Y., Xu, K., Shao, Y., Lu, Y., Shen, H., Yang, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113883 · Cited by 78

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Cha, J.-Y., Kim, D.-H., & Chun, K. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.4.133 · Cited by 71

Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans

Chen, K., Ma, J., Jia, X., Ai, W., Ma, Z., & Pan, Q. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.005 · Cited by 72

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis

Branković, M., Jovanović, I., Dukić, M., Radonjić, T., Oprić, S., Klašnja, S., & Zdravkovic, M. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095146 · Cited by 72

Lipotoxicity: Many Roads to Cell Dysfunction and Cell Death: Introduction to a Thematic Review Series

Schaffer, J. E. (2016) · Journal of Lipid Research · doi:10.1194/jlr.e069880 · Cited by 68

Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition

El-Derany, M. O., & AbdelHamid, S. G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114624 · Cited by 64

p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine

Krstić, J., Galhuber, M., Schulz, T. J., Schupp, M., & Prokesch, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030921 · Cited by 65

Characterization of Cellular Sources and Circulating Levels of Extracellular Vesicles in a Dietary Murine Model of Nonalcoholic Steatohepatitis

Li, J., Liu, H., Mauer, A. S., Lucien, F., Raiter, A. M., Bandla, H., Mounajjed, T., Yin, Z., Glaser, K. J., Yin, M., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1404 · Cited by 63

Extracellular Vesicles as Inflammatory Drivers in NAFLD

Srinivas, A. N., Suresh, D., Santhekadur, P. K., Suvarna, D., & Kumar, D. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.627424 · Cited by 65

Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets

Chen, Y., Wang, W., Morgan, M. P., Robson, T., & Annett, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148934 · Cited by 63

Identification of the genomic region under epigenetic regulation during non‐alcoholic fatty liver disease progression

Hotta, K., Kitamoto, T., Kitamoto, A., Ogawa, Y., Honda, Y., Kessoku, T., Yoneda, M., Imajo, K., Tomeno, W., Saito, S., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12992 · Cited by 59

Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake

Nie, K., Gao, Y., Chen, S., Wang, Z., Wang, H., Tang, Y., Su, H., Lu, F., Dong, H., & Fang, K. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154661 · Cited by 62

Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach

Grgurević, I., Božin, T., Mikuš, M., Kukla, M., & O’Beirne, J. P. (2021) · Cancers · doi:10.3390/cancers13225844 · Cited by 58

Treating inflammation to combat non-alcoholic fatty liver disease

Wiering, L., & Tacke, F. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 59

ENO3 promoted the progression of NASH by negatively regulating ferroptosis via elevation of GPX4 expression and lipid accumulation

Lü, D., Xia, Q., Yang, Z., Gao, S., Sun, S., Luo, X., Li, Z., Zhang, X., Han, S., Li, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-471 · Cited by 49

Attenuating Effects of Dieckol on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Decreasing the NLRP3 Inflammasome and Pyroptosis

Oh, S., Son, M., Byun, K.-A., Jang, J. T., Choi, C. H., Son, K. H., & Byun, K. (2021) · Marine Drugs · doi:10.3390/md19060318 · Cited by 52

A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Kumar, D. P., Santhekadur, P. K., Seneshaw, M., Mirshahi, F., Uram–Tuculescu, C., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.30346 · Cited by 50

Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice

Choi, S., Hwang, Y., Lee, S., Jung, H.-K., Shin, T. H., Son, Y., Park, S., Han, S. J., Kim, H. J., Lee, K. W., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.034 · Cited by 47

Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review

Głuszyńska, P., Lemancewicz, D., Dzięcioł, J. B., & Hady, H. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245721 · Cited by 51

MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM

Tian, C., Min, X., Zhao, Y., Wang, Y., Wu, X., Liu, S., Dou, W., Zhou, T., Liu, Y., Luo, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.017 · Cited by 49

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52

Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma

Raza, S., Rajak, S., Anjum, B., & Sinha, R. A. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2019.014 · Cited by 47

Changes in Key Mitochondrial Lipids Accompany Mitochondrial Dysfunction and Oxidative Stress in NAFLD

Durand, M., Coué, M., Croyal, M., Moyon, T., Tesse, A., Atger, F., Ouguerram, K., & Jacobi, D. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9986299 · Cited by 52

Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update

Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 44

Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation

Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 46

Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma

Rivera‐Esteban, J., Muñoz, S., Higuera, M., Sena, E., Bermúdez-Ramos, M., Bañares, J., Martínez-Gómez, M., Cusidó, M. S., Jiménez-Masip, A., Francque, S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.028 · Cited by 45

TRAIL deletion prevents liver inflammation but not adipose tissue inflammation during murine diet‐induced obesity

Hirsova, P., Weng, P., Salim, W., Bronk, S. F., Griffith, T. S., Ibrahim, S. H., & Gores, G. J. (2017) · Hepatology Communications · doi:10.1002/hep4.1069 · Cited by 41

Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis

Hughey, C. C., Puchalska, P., & Crawford, P. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159209 · Cited by 45

Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease

Moreno‐Vedia, J., Girona, J., Ibarretxe, D., Masana, L., & Rodríguez‐Calvo, R. (2022) · Biomedicines · doi:10.3390/biomedicines10010197 · Cited by 40

Scutellarin ameliorates hepatic lipid accumulation by enhancing autophagy and suppressing IRE1α / XBP1 pathway

Zhang, X., Huo, Z., Luan, H., Huang, Y., Shen, Y., Sheng, L., Liang, J.-Y., & Wu, F. (2021) · Phytotherapy Research · doi:10.1002/ptr.7344 · Cited by 39

Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease

Newman, L. A., Sorich, M. J., & Rowland, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072032 · Cited by 42

Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease

Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 41

Non-alcoholic fatty liver disease: Insights from sphingolipidomics

Montefusco, D. J., Allegood, J. C., Spiegel, S., & Cowart, L. A. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.078 · Cited by 38

Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis

He, W., Huang, C., Zhang, X., Wang, D., Chen, Y.-L., Zhao, Y., & Li, X. (2021) · Endocrine · doi:10.1007/s12020-021-02716-y · Cited by 36

Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma

Tian, Z., Chen, X., Yang, P., Lin, Z., Wu, W., Zhang, W., Ding, J. H., Ding, R., Zhang, X., & Dou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984728 · Cited by 40

Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances

Ding, Z., Wang, L., Sun, J., Zheng, L., Tang, Y., & Tang, H. H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1526206 · Cited by 35

Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response

Delaune, V., Orci, L. A., Lacotte, S., Peloso, A., Schrenzel, J., Lazarević, V., & Toso, C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1518424 · Cited by 46

Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease

Blencowe, M., Karunanayake, T., Wier, J. R., Hsu, N., & Yang, X. (2019) · Genes · doi:10.3390/genes10120966 · Cited by 36

Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease

Abenavoli, L., Procopio, A. C., Paravati, M. R., Costa, G., Milić, N., Alcaro, S., & Luzza, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123477 · Cited by 37

Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis

Tomita, K., Kohli, R., MacLaurin, B. L., Hirsova, P., Guo, Q., Sanchez, L. H. G., Gelbard, H. A., Blaxall, B. C., & Ibrahim, S. H. (2017) · JCI Insight · doi:10.1172/jci.insight.94488 · Cited by 35

Detection of DNA damage response in nonalcoholic fatty liver disease via p53-binding protein 1 nuclear expression

Akazawa, Y., Nakashima, R., Matsuda, K., Okamaoto, K., Hirano, R., Kawasaki, H., Miuma, S., Miyaaki, H., Malhi, H., Abiru, S., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0218-8 · Cited by 35

Exercise activates Sirt1-mediated Drp1 acetylation and inhibits hepatocyte apoptosis to improve nonalcoholic fatty liver disease

Hu, Z., Zhang, H., Wang, Y., Li, B., Liu, K., Ran, J., & Li, L. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01798-z · Cited by 33

Lipotoxicity pathways intersect in hepatocytes: Endoplasmic reticulum stress, c‐Jun N‐terminal kinase‐1, and death receptors

Akazawa, Y., & Nakao, K. (2016) · Hepatology Research · doi:10.1111/hepr.12658 · Cited by 25

Pathogenic role of lipids in non-alcoholic fatty liver disease

Shulpekova, Y. O. (2012) · DOAJ (DOAJ: Directory of Open Access Journals)

Hepatocyte Lethal and Nonlethal Lipotoxic Injury

Hirsova, P., Ibrahim, S. H., Malhi, H., & Gores, G. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-53774-0_5 · Cited by 3

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation

Ibrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278

Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis

Hirsova, P., & Gores, G. J. (2014) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2014.11.005 · Cited by 201